Skip to content
Congress·In Committee·9 months ago

Senate Bill Would Make Biosimilars Automatically Interchangeable, Cutting Drug Switching Red Tape

Also known as: Biosimilar Red Tape Elimination Act

Legislative Progress

✓ Filed
Review
Senate
House
President

Impacts

Mixed Impacts(6)
Chronic Illness
Neutral
Medicare
Neutral
Retiree
Neutral
Disability Benefits
Neutral
Medicaid
Neutral
Child Tax Credit
Neutral

Key Points

  • This bill would treat most approved biosimilar medicines as automatically interchangeable with the original biologic drug.
  • That could make it easier for pharmacies and health plans to switch to a lower-cost biosimilar, similar to how generics work for many drugs.
  • It sets a transition: new biosimilars would be interchangeable right away after approval, and older approved biosimilars would become interchangeable 60 days after the bill becomes law.
  • It keeps certain temporary exclusivity protections already in place, so automatic interchangeability could be delayed when a protected product is still in its exclusivity window.
  • It requires the federal health agency to update and revise its biosimilar guidance documents within 18 months to match the new rules.
HealthcarePrescription DrugsConsumer Protection

Milestones

2 milestones2 actions
Jun 4, 2025Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Jun 4, 2025

Introduced in Senate

What Happens Next

Projected impacts based on AI analysis

60 days after enactment

60 days after the bill becomes law, most FDA-licensed biosimilars are treated as “interchangeable.”

Pharmacies and health plans can more easily substitute biosimilars for the brand biologic (except where an existing protected exclusivity period delays it). Patients may start seeing more switches and more biosimilar options on formularies.

Within 18 months after enactment

FDA updates or withdraws older interchangeability guidance documents.

Drug companies and clinicians get clearer, updated instructions that match the new rules, which can speed up reviews and reduce confusing paperwork.

Within 18 months after enactment

FDA issues or revises guidance on what data companies must submit to show a product is biosimilar.

This can affect how quickly new biosimilars reach the market and how much they cost to develop, which can influence competition and prices.

Within 18 months after the comment period closes

After public comments close on the new guidance, FDA releases revised draft or final guidance versions.

The final guidance can lock in the practical rules companies follow, which can shape how many biosimilars get developed and how confident doctors and pharmacists feel about switching.

Related News

4 articles
Fierce Pharma·12 days ago

Senate HELP Committee chair pitches proposals for FDA reform

Senate HELP Committee Chair Bill Cassidy released a report proposing reforms to the FDA review process, including codifying the agency's stance that all approved biosimilars should be considered interchangeable. The report aligns with the goals of the Biosimilar Red Tape Elimination Act.

C=
GaBI Journal·11 months ago

Biosimilar Red Tape Elimination Act (S.2305): weakening FDA regulatory standards for biosimilars, undermining physician confidence and jeopardizing patient health

This report examines the potential risks of the Biosimilar Red Tape Elimination Act, noting that classifying all biosimilars as interchangeable without switching studies could weaken FDA standards and undermine physician confidence in pharmacy-level substitutions.

C−
The Center for Biosimilars·over 2 years ago

Senator Reintroduces Biosimilar Red Tape Elimination Act

Senator Mike Lee reintroduced the Biosimilar Red Tape Elimination Act to end switching study requirements for companies seeking interchangeability designations. The bill would amend federal code to state that all biosimilars are deemed interchangeable upon initial FDA approval.

C=

Source Information

Document Type

Congressional Bill

Official Title

Biosimilar Red Tape Elimination Act

Bill NumberS 1954
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsor

Cosponsors

(4)
D: 2R: 2

Analysis generated by AI. While we strive for accuracy, this should not be considered legal or professional advice. Always verify information with official government sources.